An oral small molecule therapy
selectively inhibiting TYK21*

DISCOVER THE FACE OF SOTYKTUTM

SOTYKTU (deucravacitinib tablets) is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

An oral small molecule therapy
selectively inhibiting TYK21*

DISCOVER THE FACE OF SOTYKTUTM

SOTYKTU (deucravacitinib tablets) is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Consider SOTYKTU

Graph icon

Superior response rates
vs. apremilast and
placebo at Week 161-3

Significantly higher PASI 90 and PASI 75 response rates seen in 2 clinical trials

SEE STUDIES
Shield with medical cross icon

Favourable
safety profile1

Most common adverse reactions (≥5%) were upper respiratory tract infection (18.9%)

REVIEW NOW
Graph icon

Convenient once-daily
oral option1*

Once-daily oral treatment with no dose adjustments required in special populations

LEARN MORE
Graph icon

Support for your
patients starts here

Enrol your patients in the BMS Patient Support Program for SOTYKTU in
3 simple steps

START NOW

Have a question?

Fill in the following form and a SOTYKTU representative will reach out to you as soon as possible. All fields are required.

Please enter Name.
Please enter the question. 0/255
*Please complete all fields.

Stay in the know

Sign up to get updates about
SOTYKTU from BMS.

Sign up for updates

BMS is leading the way

At BMS, we are committed to helping patients prevail over serious immune-related diseases such as psoriasis.
We are excited about our innovative research on the TYK2 pathways and the role they may play in dermatology.

Indication and Clinical Use:

SOTYKTU (deucravacitinib tablets) is indicated for the treatment of adult patients with moderate to severe plaque psoriasis
who are candidates for systemic therapy or phototherapy.

There are no data in pediatric patients, therefore, Health Canada has not authorized an indication for pediatric use.

Relevant Warnings and Precautions:

  • No studies on the effects of SOTYKTU on ability to drive and use machinery. Exercise caution when driving or
    operating a vehicle or potentially dangerous machinery.
  • Contains lactose. SOTYKTU should not be administered in patients with rare hereditary problems of galactose
    intolerance, total lactase deficiency, or glucose-galactose malabsorption.
  • Increased risk of infections. SOTYKTU should not be initiated in patients with any clinically important active infection
    until it resolves or is adequately treated.
  • Pre-treatment evaluation of tuberculosis (TB). Do not administer SOTYKTU to patients with active TB.
  • Avoid use of live vaccines with SOTYKTU. The response to live or non-live vaccines has not been evaluated.
  • Insufficient data to inform on risk in pregnant women.
  • It is unknown if SOTYKTU is excreted in human milk. Precaution should be exercised because many drugs can be excreted in human milk.
  • Not recommended in patients with severe hepatic impairment (Child-Pugh Class C).

For More Information:

Please consult the Product Monograph at https://www.bms.com/assets/bms/ca/documents/productmonograph/SOTYKTU_EN_PM.pdf for adverse reactions, drug interactions, and dosing information. The Product Monograph is also available by calling 1-866-463-6267.

TYK2=tyrosine kinase 2
*Clinical significance unknown.
Tablet not actual size.
References:
1. SOTYKTU Product Monograph. Bristol-Myers Squibb Canada Co. November 23, 2022. 2. Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast
in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. JAAD. 2022. doi: 10.1016/j.jaad.2022.07.002 3. Strober B, Thaçi D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial. JAAD. 2022. doi: 10.1016/j.jaad.2022.08.061

This website is best viewed using the horizontal display on your tablet device.

This website is best viewed using the vertical display on your mobile device.